Did you know?

Catalyst Biosciences announced a dividend on Wednesday, January 4th. Shareholders of record on Monday, January 16th will be paid a dividend of $0.24 per share on Thursday, January 12th. This represents a yield of 285.47%. The ex-dividend date of this dividend is Friday, January 13th. Read our dividend analysis for CBIO.This news propelled Agenus’ stock 21% higher to $3.93 in the subsequent trading session on volume eclipsing 95 million shares. ... Live Chat on The Biotech Forum has been dominated by discussion ...First Quarter 2023 Financial Results: We ended our first quarter 2023 with a cash, cash equivalent and short-term investment balance of $189.2 million, compared to $193.4 million at December 31, 2022. Since quarter end we have raised $13.6 million through sales under our at market issuance sales agreement. For the first quarter ended March 31 ...Agenus Inc. analyst ratings, historical stock prices, earnings estimates & actuals. AGEN updated stock price target summary.Harnessing the power of the immune system to fight cancer is a big deal and Agenus Inc. ( AGEN 0.95%) looks like a great way to follow the trend. This stock trades like a small-cap biotech, but a ...AGENUS INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) May 10, 2022 at 07:55 am EDT ... In October 2021, MiNK Therapeutics completed an initial public offering of 3,333,334 shares of its common stock, trading on the Nasdaq Global Market under the ticker symbol "INKT", ...Find the latest Agenus Inc. (AGEN) stock quote, history, news and other vital information to help you with your stock trading and investing.Get the latest Agenus Inc (AGEN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. All about the Miles to Memories Podcast including how to subscribe. Join us weekly for the best miles & points discussion plus expert travel tips. The Miles to Memories podcast is here! We release a new episode every Thursday. Want more? Sh...Agenus Inc. has a market cap of $558mn and a cash balance of $193mn. R&D expenses were $57mn for the three months ended March 31, while G&A expenses were $18mn. At that rate, they have fewer than ...Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LEXINGTON, Mass., September 01, 2023--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus' Board of Directors granted, as of September 1, 2023 ("Grant Date"), inducement awards to Robin Taylor, Ph.D. in ...Latest News Industries Currency Convertor Agenus Inc. (AGEN) NasdaqCM - NasdaqCM Real-time price. Currency in USD Add to watchlist 1.1400 -0.0400 (-3.39%) At close: 04:00PM EDT 1.1300 -0.01...Oct 10, 2023 · Aug. 28. BU. Agenus to Lay Off 25% of Workforce for Expected Savings of $2.8 Million. Aug. 23. MT. Agenus to Lay Off Roughly 25% of Workforce. Aug. 23. MT. Agenus Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers. Find the latest Agenus Inc. (AGEN) stock discussions in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.agenus is an immunology company discovering and developing novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases. we are a dedicated group of scientists, researchers, biotechnologists, physicians, and businesspeople working together toward one goal: to discover and develop therapies that can unleash the innate power of the body’s immune system to treat and ... 1.1800. -0.0100. -0.84%. LEXINGTON, Mass., May 09, 2023--Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company with an extensive pipeline of clinical and preclinical-stage cancer treatments ...According to 5 analysts, the average rating for AGEN stock is "Strong Buy." The 12-month stock price forecast is $8.12, which is an increase of 658.88% from the latest price.AGEN Stock 12 Months Forecast. $7.50. (552.17% Upside) Based on 4 Wall Street analysts offering 12 month price targets for Agenus in the last 3 months. The average price target is $7.50 with a high forecast of $8.00 and a low forecast of $6.00. The average price target represents a 552.17% change from the last price of $1.15.Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LEXINGTON, Mass., September 01, 2023--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus’ Board of Directors granted, as of September 1, 2023 ("Grant Date"), inducement awards to Robin Taylor, Ph.D. in ...Agenus (AGEN) stock price, charts, trades & the US's most popular discussion forums. Free forex prices, toplists, indices and lots more.

$-0.84 Market Cap $390.96 M Shares Outstanding 379.57 M Public Float 370.25 M Yield AGEN is not currently paying a regular dividend. Latest Dividend N/A Ex-Dividend Date …Stock control is important because it prevents retailers from running out of products, according to the Houston Chronicle. Stock control also helps retailers keep track of goods that may have been lost or stolen.Agenus Inc. (AGEN) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 1.0700 0.0000 (0.00%) At close: 04:00PM EDT Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical ...

Agenus Inc. (NASDAQ:AGEN Get Free Report) was the recipient of a large growth in short interest in August. As of August 15th, there was short interest totalling 26,320,000 shares, a growth of 36.2% from the July 31st total of 19,330,000 shares. Based on an average daily trading volume, of 5,... Shares of Agenus Inc. (NASDAQ:AGEN Get Free Report ...More Good News: ASCO Presentation of Agenus' AGEN1181 by Dr. Steven O'D: Kirk ©-5/29/2020: 128: I wasn't aware their cancer therapy would also help with COVID-19, but it ma: Kirk ©-5/13/2020: 127: It is great to see good news move the stock! First QS-21 Royalty Payment Due to: Kirk ©-3/10/2020: 126: Agenus Pipeline Slide agenusbio.com ...…

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Before the latest update, the analysts we. Possible cause: Shares of clinical-stage cancer immunotherapy company Agenus ( AGEN 0.95.